Revitope Oncology Revitope Oncology is a biotechnology company focused on developing of T cell redirecting biologics. | ![]() GlycoMimetics GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers. | ![]() Heidelberg Pharma Heidelberg Pharma is a drug development company that provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries. | ||
Founding Date | Founding Date 2016 | Founding Date 2003 | Founding Date 1994 | Founding Date 1997 |
Type | Type Private | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Cambridge, US HQ | Locations Rockville, US HQ | Locations Alameda, US HQ | Locations Ladenburg, DE HQ Ladenburg, DE |
Employees | Employees 717% increase | Employees 5025% increase | Employees 1,14712% decrease | Employees 60 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 31.6 m | Valuation ($) 8.2 b | Valuation ($) 158.3 m |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $10.8m (FY, 2025) | Revenue (est.) $2.3b (FY, 2025) | Revenue (est.) €1.5m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $83.7m (FY, 2025) | Cost of goods (€2.5m) (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $2.2b (FY, 2025) | Gross profit €6.3m (FY, 2025) |
Net income | Net income N/A | Net income ($153.9m) (FY, 2025) | Net income $782.6m (FY, 2025) | Net income (€42.3m) (FY, 2025) |

GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers.
View company
Exelixis is an oncology company that develops cancer treatments.
View company
Heidelberg Pharma is a drug development company that provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries.
View company